Physician profile
Daniel W Wells
NPI 1548340375
$1,449.66
in general payments reported to CMS, 2019-2025
24 companies · $784 in 2025
The $784 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.77 · 2020: $64.49 · 2021: $15.88 · 2022: $55.89 · 2023: $43.42 · 2024: $456 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $249.77 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $223.85 | 2019-2025 | |
| Abbvie INC. | $135.27 | 2024-2025 | |
| Novo Nordisk INC | $119.21 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $117.09 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Abbott Laboratories | $65.52 | 2023-2025 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit |
| Phathom Pharmaceuticals, INC. | $51.47 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $49.79 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.02 | 2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $44.75 | 2024-2025 | Breztri |
| Exact Sciences Corporation | $42.04 | 2024-2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $37.07 | 2020 | |
| Ironshore Pharmaceuticals INC. | $33.28 | 2024 | |
| Collegium Pharmaceutical, INC. | $31.20 | 2025 | Jornay Pm |
| Bayer Healthcare Pharmaceuticals INC. | $28.56 | 2020-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.51 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $23.59 | 2025 | |
| Gilead Sciences, INC. | $23.26 | 2025 | |
| Seqirus USA INC | $20.39 | 2025 | Flucelvax, Fluad |
| Medtronic, INC. | $19.95 | 2025 | Venaseal |
| Organon LLC | $19.76 | 2024-2025 | Jada System |
| Inspire Medical Systems, INC. | $17.66 | 2025 | Inspire |
| Corium, LLC | $14.02 | 2024 | Azstarys |
| Merck Sharp & Dohme LLC | $12.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.